Table 2 Summary of results of loss of heterozygosity studies

From: Loss of heterozygosity identifies genetic changes in chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes and chronic myelomonocytic leukemia

 

D7S2554

D8S263

D9S157

D9S161

D13S319

TP53

D20S108

CIMF

27% (3/11)

50% (5/10)

27% (3/11)

18% (2/11)

36% (4/11)

25% (3/12)

30% (3/10)

ET

30% (3/10)

18% (2/11)

36% (4/11)

27% (3/11)

30% (3/10)

27% (3/11)

10% (1/10)

PV

25% (1/4)

0% (0/4)

0% (0/4)

40% (2/5)

0% (0/3)

25% (1/4)

40% (2/5)

CML

0% (0/3)

50% (1/2)

0% (0/2)

50% (1/2)

0% (0/3)

25% (1/4)

NP

ALL CMPD

25% (7/28)

30% (8/27)

25% (7/28)

28% (8/29)

26% (7/27)

26% (8/31)

28% (7/25)

MDS

50% (3/6)

0% (0/5)

0% (0/6)

33% (2/6)

17% (1/6)

33% (2/6)

17% (1/6)

CMML

25% (2/8)

43% (3/7)

38% (3/8)

25% (2/8)

50% (4/8)

43% (3/7)

29% (2/7)

  1. CIMF, chronic idiopathic myelofibrosis; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; CMPD, chronic myeloproliferative disorder; ET, essential thrombocythemia; MDS, myelodysplastic syndrome; NP, not performed; PV, polycythemia vera.
Back to article page